Relmada Therapeutics logo
Relmada Therapeutics
RLMD | NASDAQ
Chart Builder DCF Calculator
$3.61
-$0.60 (-14.25%)
At close: Nov 16, 2026, 4:00 PM ET
$3.61
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Relmada Therapeutics Company Profile

Company profile explained

Company Profile

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

Key Executives

Name Position
Sergio Traversa Chief Executive Officer & Director
Maged S. Shenouda Chief Financial Officer
Paul E. Kelly Chief Operating Officer & Director
Andrew Cutler Senior Clinical Development Advisor
Bipin K. Dalmia Chief Business Officer
Charles S. Ence Chief Accounting & Compliance Officer
Gina DiGuglielmo Vice President & Head of Clinical Operations
Raj S. Pruthi Chief Medical Officer of Urology
Richard Mangano Consultant

Latest SEC Filings

Date Type Title
Sep 11, 2026 4 Filing
Sep 11, 2026 4 Filing
Sep 08, 2026 8-K Current Report
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 06, 2026 8-K Current Report
Aug 06, 2026 10-Q Quarterly Report
Jul 29, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Jul 28, 2026 8-K Current Report
Jun 22, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Jun 18, 2026 S-8 Filing
View All SEC Filings ➞
Relmada Therapeutics
Relmada Therapeutics logo
Country United States
IPO Date Jun 20, 2014
Industry Biotechnology
Sector Healthcare
Employees 17
CEO Sergio Traversa

Contact Details

2222 Ponce de Leon Blvd. Coral Gables, Florida 33134 United States

Stock Details

Ticker Symbol RLMD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001553643
CUSIP Number 75955J402
ISIN Number US75955J4022
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.